Skip to main content

Table 1 An overview of patient measurements

From: Clinical evaluation of respiration-induced attenuation uncertainties in pulmonary 3D PET/CT

  Affected lung Tumour SUV max Tumour size (CC) Motion amplitude tumour (mm) ∆CT number (EI-EE) (Lung ROI) ∆SUV max (EI-EE) (Tumour) ∆SUV max (3D-phase) (Tumour) ∆SUV mean (EI-EE) (Lung ROI) ∆SUV mean (3D-phase) (Lung ROI) ∆SUV mean (EI-EE) (Muscle ROI) ∆SUV mean (3D-phase) (Muscle ROI)
#1 Right 15.1 94.0 1.7 −3.6% 0.3% −5.4% −0.5% 0.2% 0.0% 0.2%
#2 Right 18.2 79.4 1.4 −21.8% −3.9% −0.3% −4.1% −4.0% 0.4% 2.7%
#3 Right 19.9 22.4 2.8 −10.2% −1.3% 0.6% −1.8% 4.9% 0.7% 1.3%
#4 Right 11.1 30.9 1.4 −20.2% −2.4% −1.0% −4.1% −1.3% 1.0% 1.9%
#5 Right 23.4 15.5 3.3 −4.5% 1.3% −1.7% −0.6% 1.8% 0.0% 4.5%
#6 Left 2.7 12.2 5.5 −14.0% −5.4% 1.5% −2.8% 1.3% 0.1% 3.0%
#7 Right 3.6 1.3 2.0 −14.6% −5.8% 0.3% −4.3% 5.2% −1.5% 0.1%
  Right 11.1 1.0 2.0 - −7.7% −8.4% - - - -
#8 Left 14.2 17.7 7.3 −29.0% −8.4% −2.6% −8.1% −1.7% −0.2% 0.8%
#9 Left 14.5 19.8 16.4 −21.0% −9.3% −8.8% −8.0% −5.7% −1.4% 8.2%
#10 Right 9.8 2.2 8.6 −12.8% −7.6% 1.4% −3.1% −0.5% 0.2% 0.0%
#11 Right 24.8 33.7 1.7 −25.6% −2.0% −1.1% −5.0% −0.6% 0.8% 3.6%
#12 Left 24.1 94.1 1.7 −29.7% −4.5% −0.4% −12.2% −3.6% 0.7% 1.5%
#13 Right 5.9 3.0 6.6 −12.9% −5.4% 3.0% −2.8% 2.0% −1.1% 1.6%
  Right 3.7 8.9 5.7 - −6.2% 2.8% - - - -
#14 Left 10.8 25.5 5.2 −17.9% −5.3% −3.6% −4.8% 3.8% 1.5% −2.7%
#15 Right 13.6 23.4 27.1 −20.6% −9.5% −2.5% −8.0% −0.3% −1.4% −0.4%
#16 Right 12.0 23.0 4.1 −8.9% −6.9% 4.8% 0.5% −18.5% −0.5% 1.1%
#17 Right 7.5 18.8 4.2 −23.3% −7.8% −0.5% −3.1% 1.9% 1.2% −0.7%
#18 Left 3.0 4.9 1.4 1.3% 0.2% 0.2% 0.4% 1.2% 0.3% 1.9%
#19 Left 3.4 2.9 12.7 −18.2% −5.8% −21.1% −2.2% −6.7% 1.8% 4.0%
#20 Left 10.7 3.3 6.5 −13.0% −3.9% −3.7% −2.7% 0.7% −0.6% 1.3%
#21 Left 17.2 6.2 2.0 −15.1% −1.2% −1.1% −4.7% −0.7% 0.6% 0.9%
#22 Left 7.5 1.9 2.4 −5.7% −0.2% 1.0% 1.6% 2.1% 1.2% 2.6%
  Right 7.1 1.9 13.4 −19.5% −5.7% −4.2% −1.6% 1.7% 0.8% 2.9%
#23 Left 4.0 2.0 2.2 −11.4% −0.6% 5.9% −2.1% −0.1% −1.9% −2.1%
  Right 9.0 2.0 2.4 −12.8% −6.0% 0.7% −1.4% −4.0% −1.1% −6.8%
#24 Right 16.2 13.2 8.2 −18.6% −2.5% −3.7% −2.3% −1.0% −0.5% −0.2%
#25 Right 9.5 16.5 2.4 −18.0% −9.2% −8.4% −3.8% −0.1% −0.3% 1.9%
#26 Right 5.3 5.6 9.0 −13.9% −3.2% 6.2% −2.1% −2.3% 0.7% −1.2%
  Right 3.7 2.3 5.1 - −1.0% 0.4% - - - -
  Left 4.9 2.4 3.5 −18.1% −3.2% 0.7% −3.7% −0.7% 0.7% 0.9%
#27 Left 16.9 17.5 1.4 −23.2% −1.9% −2.7% −9.6% 1.1% 0.6% 1.6%
#28 Left 26.2 21.5 4.4 −15.4% −1.5% −2.8% −2.0% 0.4% 0.6% 0.5%
#29 Right 23.9 25.0 1.4 −18.3% −3.0% −4.8% −4.6% 2.2% 0.0% 3.0%
#30 Right 5.2 1.8 7.9 −5.4% −6.7% −4.1% −0.1% −5.5% 0.7% 2.4%
#31 Left 15.4 3.1 5.7 −18.3% −3.2% 3.0% −5.3% −5.6% −0.3% 5.2%
#32 Left 3.7 4.8 2.0 −11.5% −1.4% 1.7% −1.8% −1.3% 0.0% 1.8%
Mean   11.5 17.5 5.3 −15.6% −4.1% −1.6% −3.5% −1.0% 0.1% 1.4%
STDEV   7.0 23.4 5.1 7.0% 3.0% 4.8% 3.0% 4.2% 0.9% 2.5%
Min   2.7 1.0 1.4 −29.7% −9.5% −21.1% −12.2% −18.5% −1.9% −6.8%
Max   26.2 94.1 27.1 1.3% 1.3% 6.2% 1.6% 5.2% 1.8% 8.2%
T-test significance       5.56E-08 0.0036 4.1E-06 0.13 0.52 0.0062
  1. An overview with the individual patient measurements. For the SUV values, we also determined the significance level, with the null hypothesis that they were the same, using a two-tailed paired Student's T-test. When two tumours are present in the same lung, the measurements of that lung are only provided once.